Company Profile For Anesiva, Inc.

Anesiva, Inc. (Anesiva) is a biopharmaceutical company focused on the development and commercialization of therapeutic treatments for pain management. Its portfolio includes two products. Adlea, a long-acting, site-specific, non-opioid analgesic, is being developed for moderate to severe pain, and has completed multiple Phase II trials in post-surgical, musculoskeletal and neuropathic pain and Phase III trials in bunionectomy and total knee arthroplasty (TKA, or total knee replacement surgery). The Company is initially pursuing an indication for Adlea for the management of acute pain associated with orthopedic surgeries. Zingo (lidocaine hydrochloride monohydrate) powder intradermal injection system, was approved by the Food and Drug Administration (FDA) in August 2007, to reduce the pain associated with peripheral intravenous (IV) insertions or blood draws in children 3 to 18 years of age. Zingo was approved in January 2009, to reduce the pain associated with blood draws in adults.

BRIEF: For the six months ended 30 June 2009, Anesiva, Inc.'s revenues totaled $0 down from $303K. Net loss from continuing operations decreased 60% to $11.1M. Revenues reflect a decrease in demand for the Company's products. Lower loss reflects a decrease in research & development due to decreased trail cost, presence of gain on sale of assets, lower interest & other expense and decrease in general and administrative expenses.